Oncology

Young children had more than twice the risk for overdose compared to children whose mothers were prescribed nonsteroidal anti-inflammatory drugs (NSAIDs) rather than opioids.

Top news of the week in oncology and cancer drug development.

The Akt protein is crucial for T cells to transform into memory T cells.

SF2523 can dually inhibit a protein and an enzyme associated with cancer.

Cancer cells adjusted to have normal circadian rhythm slowed tumor growth.

Tumor growth can be fueled by sleep disruption.

The Iowa Department of Public Health released its first report on hepatitis C virus.

Extrachromosomal oncogene helps drive tumor evolution and heterogeneity.

Lenalidomide (Revlimid) maintenance improved survival in multiple myeloma patients following a stem cell transplant.

Application filed for ceritinib (Zykadia) as a first-line treatment for patients with metastatic non-small cell lung cancer.

Top news of the day from across the health care landscape.

Zykadia granted breakthrough therapy designation for ALK+ metastatic non-small cell lung cancer with brain metastases.

The FDA has accepted Novartis’ supplemental new drug application (sNDA) for filing and granted priority review for the expanded use of a new cancer drug.

Physical activity drops during and after cancer treatment.

Consumption of beta-cryptoxanthin reduced lung cancer risk up to 63%.

SMAC mimetics and immune checkpoint inhibitors, together, promote tumor immunity against deadly brain cancer.

Top news of the week in oncology and cancer drug development.

Smokers who receive telephone-based smoking cessation counseling shortly after undergoing lung cancer screening may be more likely to quit smoking, a new Georgetown Lombardi-led study finds.

Targeted therapy improves survival rates for dogs with hemangiosarcoma.

Community Oncology Alliance at odds with the opinion of pharmacy benefit managers regarding direct and indirect remuneration fees.

The World Health Organization seeks to improve early cancer detection to increase survivors and cut treatment costs.

Aggressive cancers found more susceptible to combination treatment compared with monotherapy.

Stakeholders debate the benefits of direct and indirect remuneration fees.

Certain BRCA1 mutations reduce the risk of developing leukemia.

Onset or rapid deterioration of diabetes may be an indicator of hidden pancreatic cancer.

Top news of the day from across the health care landscape.

Unreliable data found in reports that did not support the professor’s hypothesis in cancer research.

Why are some patients with cancer unresponsive to immunotherapies?